A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry

Genome-wide association studies (GWAS) have identified 36 loci associated with body mass index (BMI), predominantly in populations of European ancestry. We conducted a meta-analysis to examine the association of >3.2 million SNPs with BMI in 39,144 men and women of African ancestry and followed up the most significant associations in an additional 32,268 individuals of African ancestry. We identified one new locus at 5q33 (*GALNT10*, rs7708584, $P = 3.4 \times 10^{-11}$) and another at 7p15 when we included data from the GIANT consortium (*MIR148A-NFE2L3*, rs10261878, $P = 1.2 \times 10^{-10}$). We also found suggestive evidence of an association at a third locus at 6q16 in the African-ancestry sample (*KLHL32*, rs974417, $P = 6.9 \times 10^{-8}$). Thirty-two of the 36 previously established BMI variants showed directionally consistent effect estimates in our GWAS (binomial $P = 9.7 \times 10^{-7}$), five of which reached genome-wide significance. These findings provide strong support for shared BMI loci across populations, as well as for the utility of studying ancestrally diverse populations.

There are notable racial and ethnic disparities in the prevalence of obesity in the United States; nearly 50% of African-American adults are classified as obese compared to 35% of non-Hispanic whites[1]. GWAS have identified 36 BMI loci at statistically significant levels ($P < 5 \times 10^{-8}$)[2–13], 32 of which were identified in individuals of European ancestry[3–8] and 4 of which were identified in east Asian populations[9,10]. Large GWAS of BMI in populations of African ancestry are lacking and will be important for identifying genetic variants that are unique and/or of greater importance to this population[14–17]. In this study we conducted a large GWAS meta-analysis of BMI in men and women of African ancestry to search for new loci and tested associations with common variation at the 36 known loci to better understand their relevance in populations of African ancestry.

We included 36 GWAS, totaling 39,144 men and women of African ancestry, in the stage 1 meta-analysis of as many as 3,283,202 (minor allele frequency (MAF) >1%) genotyped and imputed SNPs (Online Methods, **Supplementary Tables 1–3** and **Supplementary Note**). After applying both study-specific and overall stage 1 genomic-control corrections (**Supplementary Table 2**), 11 SNPs at five loci achieved genome-wide significance ($P < 5 \times 10^{-8}$) (**Table 1**, **Fig. 1** and **Supplementary Fig. 1**). Four of these loci are known BMI loci (1q25, *SEC16B*; 4p12, *GNPDA2*; 16q12, *FTO*; and 18q21, *MC4R*). The fifth locus, at 5q33 (rs7708584, approximately 27 kb upstream

of *GALNT10*, $P = 8.02 \times 10^{-9}$), has not been previously associated with BMI at genome-wide significant levels in any population.

We subsequently selected the 1,500 most significantly associated SNPs from stage 1 ($P < 1.19 \times 10^{-3}$) and examined associations with BMI in an independent sample of 6,817 men and women of African ancestry from seven additional studies (stage 2) (Online Methods, **Supplementary Tables 1–3** and **Supplementary Note**). Of these 1,500 SNPs, 179 replicated at nominal significance ($P < 0.05$) and had effects that were directionally consistent with those in stage 1 (**Supplementary Table 4**). A meta-analysis of stages 1 and 2 revealed a second new locus, 6q16 (rs974417, located in an intronic region of *KLHL32*; stage 2 $P = 3.5 \times 10^{-3}$, combined stages 1 and 2 $P = 2.2 \times 10^{-8}$), and confirmed our finding at rs7708584 on 5q33 near *GALNT10* (stage 2 $P = 9.4 \times 10^{-3}$, combined stages 1 and 2 $P = 2.2 \times 10^{-10}$). We further examined the associations of these two variants in a third stage composed of 25,451 individuals of African ancestry from an additional 12 studies. We found support for an association with both variants, although the strength of the association was greater for rs7708584 (*GALNT10*, $P = 7.1 \times 10^{-3}$) than for rs974417 (*KLHL32*, $P = 0.09$). In combining results across all three stages ($n = 71,412$), rs7708584 (*GALNT10*) was significantly associated with BMI ($P = 3.4 \times 10^{-11}$), whereas rs974417 (*KLHL32*) was nearly genome-wide significant ($P = 6.9 \times 10^{-8}$) (**Table 1** and **Fig. 2a,b**).

To identify additional new loci that may be of importance across populations, we examined the 1,500 most significant SNPs from stage 1 in publicly available data from the GIANT consortium of ~124,000 individuals European ancestry[7] (Online Methods). rs7708584 (*GALNT10*) was significantly associated with BMI in European-ancestry populations (effect allele frequency (EAF) = 0.42, $P = 1.2 \times 10^{-5}$) but rs974417 (*KLHL32*) was not (EAF = 0.85, $P = 0.45$), although it was directionally consistent. Through a meta-analysis of individuals of European and African ancestry, we identified an additional new variant at 7p15 (rs10261878) that was also associated with BMI in European-ancestry populations (GIANT EAF = 0.94, $P = 2.2 \times 10^{-5}$). rs10261878 on 7p15 is located in an intergenic region 39 kb upstream of *MIR148A* (encoding miRNA-148a) and approximately 241 kb upstream of *NFE2L3*. This variant was positively associated with BMI in stages 1 ($P = 1.7 \times 10^{-4}$) and 3 ($P = 1.0 \times 10^{-3}$) in the African-ancestry GWAS, with a directionally consistent but nonsignificant association in the smaller stage 2 ($P = 0.33$) (**Fig. 2c** and **Supplementary Table 5**). In combining results across studies of African (stages 1, 2 and 3) and European ancestry (combined $n = 194,247$), both rs7708584 (*GALNT10*, $P = 5.1 \times 10^{-14}$) and

Table 1 Summary of the eight independent SNPs that were associated with BMI at genome-wide significant ($P < 5.0 \times 10^{-8}$) levels in men and women of African ancestry

	Previously identified BMI loci				Newly identified BMI loci			
	rs543874	rs7586879	rs348495	rs17817964	rs6567160	rs7708584	rs974417	rs10261878[d]
Nearest gene	*SEC16B*	*ADCY3*	*GNPDA2*	*FTO*	*MC4R*	*GALNT10*	*KLHL32*	*MIR148A-NFE2L3*
Chr.	1	2	4	16	18	5	6	7
Position (build 37)	177889480	25116977	45184442	53828066	57829135	153543466	97419598	25917070
Alleles[a]	G/A	T/C	G/A	T/C	C/T	A/G	C/T	C/A
EAF[b]	0.25	0.77	0.34	0.12	0.21	0.32	0.66	0.44
Stage 1								
n	38,899	38,948	39,097	39,080	39,103	38,219	39,120	39,101
β (s.e.)	0.057 (0.009)	0.042 (0.010)	0.048 (0.009)	0.074 (0.012)	0.062 (0.010)	0.050 (0.009)	0.040 (0.008)	0.030 (0.008)
P	1.80×10^{-10}	1.05×10^{-5}	2.70×10^{-8}	2.27×10^{-9}	2.41×10^{-10}	8.02×10^{-9}	1.49×10^{-6}	1.66×10^{-4}
Stage 2								
n	6,805	6,817	6,817	6,769	6,817	6,817	6,816	6,817
β (s.e.)	0.074 (0.020)	0.073 (0.020)	0.067 (0.021)	0.068 (0.027)	0.045 (0.021)	0.047 (0.018)	0.053 (0.018)	0.017 (0.017)
P	1.49×10^{-4}	3.12×10^{-4}	1.19×10^{-3}	0.012	0.032	9.35×10^{-3}	3.47×10^{-3}	0.330
Stage 3								
n						25,337	25,451	25,308
β (s.e.)	N/A	N/A	N/A	N/A	N/A	0.026 (0.010)	0.015 (0.009)	0.029 (0.009)
P						7.08×10^{-3}	0.091	1.01×10^{-3}
Combined								
n	45,704	45,765	45,914	45,849	45,920	70,373	71,387	194,931
β (s.e.)	0.060 (0.008)	0.047 (0.009)	0.051 (0.008)	0.073 (0.011)	0.059 (0.009)	0.040 (0.006)	0.031 (0.006)	0.032 (0.005)
P	2.00×10^{-13}	3.60×10^{-8}	1.60×10^{-10}	1.05×10^{-10}	2.96×10^{-11}	3.37×10^{-11}	6.88×10^{-8}	1.23×10^{-10}
Explained variance[c] (%)	0.21	0.19	0.20	0.10	0.07	0.04	0.02	0.03

[a]The effect allele is listed first. [b]The frequencies shown are from the stage 1 sample. [c]Calculated using the results from stage 2 for previously identified BMI loci and results from stage 2 and stage 3 for newly identified BMI loci; the total fraction of variance explained was calculated using the formula $[2f(1 - f) \times a^2] \times 100$, where f is the frequency of the variant, and a is the additive effect of the variant[3]. [d]Shown are the combined results from African-ancestry stages 1, 2, 3 and GIANT (where the GIANT data are $n = 123,706$, β (s.e.) = 0.045 (0.011) and $P = 2.21 \times 10^{-5}$). Chr., chromosome; EAF, effect allele frequency; β (beta estimate) reported in inverse normally transformed units; s.e., standard error. P values for between-study heterogeneity were all >0.1.

rs10261878 (*MIR148A-NFE2L3*, $P = 1.2 \times 10^{-10}$) were significantly associated with BMI; rs974417 (*KLHL32*) did not meet the genome-wide significance threshold ($P = 5.7 \times 10^{-6}$). In individuals of east Asian descent from the AGEN[10] and RIKEN[9] consortia ($n = 27,715$ and $n = 26,620$, respectively) (**Fig. 3**, **Supplementary Table 6** and Online Methods), rs7708584 (*GALNT10*, $P = 0.002$) and rs974417 (*KLHL32*, $P = 0.023$) were directionally consistent and significantly associated with BMI, whereas rs10261878 (*MIR148A-NFE2L3*) was neither directionally consistent nor statistically significantly associated with BMI ($P = 0.053$). We then examined the associations with BMI in children of African ancestry ($n = 3,751$) (Online Methods) and found that for all three SNPs, the associations were directionally consistent but did not reach statistical significance ($P > 0.05$) (**Supplementary Table 7**).

To further understand differences by ancestral background as well as characterize the functional and genetic epidemiologic architecture of the two new BMI loci (5q33, *GALNT10*; and 7p15, *MIR148A-NFE2L3*) and the suggestive locus at 6q16 (*KLHL32*), we performed several additional analyses. Local ancestry adjustment (in 69% of the stage 1 sample; Online Methods) resulted in numerically similar effect estimates (**Supplementary Table 8**), and we did not detect evidence of significant effect heterogeneity in analyses stratified by local ancestry (**Supplementary Table 9**). We found that the three BMI loci were associated with waist circumference (among $n \approx 20,000$ individuals, many of which overlap those studied here) but not with BMI-adjusted waist circumference, waist-to-hip ratio or height[18] (**Supplementary Table 10**); however, SNPs in this region have been associated with waist-to-hip ratio in Europeans, although at SNPs that are not in linkage disequilibrium (LD) with our index SNP[19]. We found no evidence of pleiotropy with

adiposity-related metabolic traits using GWAS data provided by trait-specific consortia in men and women predominantly of European ancestry[20–24] (**Supplementary Table 11**).

We examined associations with BMI in our African-ancestry stage 1 sample of the index SNPs reported for the 36 previously established BMI loci in the European and Asian populations[7,9,10] (**Fig. 3** and **Supplementary Table 12**). The associations were directionally consistent with the effects reported in the original papers for 32 of the 36 established BMI loci (binomial test of direction $P = 9.7 \times 10^{-7}$), 16 of which associated with BMI at $P < 0.01$ (binomial test $P < 1.0 \times 10^{-15}$) (**Supplementary Table 12**).


Figure 1 Manhattan plot showing results of the BMI association meta-analysis in the stage 1 studies. Colored genomic loci indicate new associations (red) and those detected previously (blue).

Figure 2 Regional plots of three new genome-wide significant loci identified in men and women of African ancestry. (**a**–**c**) rs7708584 (in the *GALNT10* region; **a**), rs974417 (in the *KLHL32* region; **b**) and rs10261878 (in the *MIR148A-NFE2L3* region; **c**). In **a** and **b**, the stage 1 *P* value is represented by a purple circle, and the combined stages 1, 2 and 3 *P* value is represented by a purple square; in **c**, the stage 1 *P* value is represented by a purple circle, the African-ancestry combined stages 1, 2 and 3 *P* value is represented by a purple diamond, and the combined African ancestry and GIANT consortium *P* value is represented by a purple square. SNPs are plotted by their position within 500 kb on either side of the index SNP on the chromosome against their association (−log$_{10}$ *P*) with BMI using the stage 1 data. SNPs surrounding the top SNPs are colored to indicate the local LD structure using pairwise r^2 data from the May 2012 AFR panel of 1000 Genomes.

Using the results from the stage 1 meta-analysis, we searched for common variants within the established loci that better captured the association of the index SNP reported in the European and Asian populations. Seven regions (*PTBP2*, *TMEM18*, *DNAJC27* (previously known as *RBJ*), *NUDT3*, *BDNF*, *FTO* and *MC4R*) harbored at least one variant that was correlated with the index SNP in the referent population ($r^2 \geq 0.4$) and was associated with BMI in the African-ancestry GWAS at a significance level that was at least one order of magnitude greater than that observed for the index SNP (Online Methods, **Supplementary Table 13** and **Supplementary Fig. 2a–g**). These variants were also associated with BMI in the GIANT consortium (**Supplementary Table 13**) and are probably better markers of the biologically functional allele, at least in populations of African ancestry. We also interrogated the evidence for possible independent secondary signals by visual inspection of all *P* values of SNP-BMI associations for SNPs with $r^2 < 0.2$ within the 1-Mb region of the index SNP. We did not detect evidence of independent secondary

signals at any of the known BMI loci at $P < 6.7 \times 10^{-6}$ (Online Methods). For most loci, the genetic data from African-ancestry populations may assist in refining the location of the risk variant, as there are fewer markers correlated with the strongest signals and/or a more narrowed region in which any proxies reside in this population (**Supplementary Fig. 3**).

To direct us to positional candidate genes, we examined the *cis* associations between the index SNP and expression of gene transcripts within the flanking 1-Mb region (500 kb on each side) in human brain, subcutaneous and omental adipose tissue and liver[25–28] (Online Methods and **Supplementary Table 14**). rs7708584 near *GALNT10* showed nominally significant (*P* < 0.05) associations with GALNT10 expression (for two of the three transcripts available) in liver, omental fat and subcutaneous fat (*P* = 0.048, *P* = 0.00010 and *P* = 0.00017, respectively). We also found suggestive *cis* associations for rs10261878 near *NFE2L3* with NFE2L3 expression in the same three tissues (*P* = 0.039, *P* = 0.015 and *P* = 0.036 for liver, omental fat and subcutaneous fat, respectively). However, despite the consistent associations observed for our lead SNPs in the *GALNT10* and *NFE2L3* loci, other nearby SNPs showed stronger association with the expression levels of the respective transcripts (**Supplementary Fig. 4**). Subsequent conditional analyses adjusting for the most significant expression quantitative trait locus (eQTL) SNP in the region abolished the *cis* associations between the BMI-associated SNPs and the respective transcript expression levels (**Supplementary Table 15**). Taken together, these eQTL analyses could not confirm that the identified BMI-associated SNPs affect GALNT10 and NFE2L3 expression directly.


Figure 3 Effect estimates (95% confidence intervals) per BMI-increasing allele for the three new loci discovered in individuals of African ancestry (shown in the first section in descending order of the effect size in this population), the 32 loci discovered in individuals of European ancestry (shown in the second section in descending order of their effect size) and the 4 loci discovered in individuals of Asian ancestry (shown in the third section in descending order of their effect size). Results for individuals of African ancestry are depicted as red dots (combined stages 1, 2 and 3 for new loci and stage 1 for previously discovered loci); results for individuals of European ancestry are depicted as black squares[7], and results for individuals of Asian ancestry are depicted as green triangles[9,10].

We did not find nonsynonymous SNPs in *GALNT10*, *NFE2L3* or *KLHL32* that were correlated ($r^2 > 0.2$) with the most significant SNPs in the 1000 Genomes Project African-ancestry populations (AFR). However, we did detect a number of correlated SNPs ($r^2 > 0.5$) in regulatory sequences determined on the basis of overlapping chromatin marks in multiple cell types, including brain and adipose tissue (Online Methods). Many of these SNPs (or good proxies in the 1000 Genomes Project AFR, with an r^2 range of 0.59–1.0), which are located in putative enhancer and promoter regions, had only marginally weaker associations in stage 1 than the most significant SNPs reported in these regions (**Supplementary Tables 16–19** and **Supplementary Fig. 5a–c**). Together these data suggest that the biologically relevant variants in all three regions may be regulatory in function.

The variant rs7708584 at chromosome 5q33 is located upstream of *GALNT10* (encoding UDP-N-acetyl-α-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 10), which catalyzes the first step in the synthesis of mucin-type oligosaccharides (**Supplementary Note**). GALNT10 is highly expressed in the small intestine and at intermediate levels in the stomach, pancreas, ovary, thyroid gland and spleen[29]. Suggestive associations between BMI and *GALNT10* have been observed in a smaller sample of African Americans[14] that was included in the present stage 1 meta-analysis, although the lead SNP differed (rs2033195) and showed only moderate LD ($r^2 = 0.27$) with the lead SNP we discovered here. The variant at 7p15, rs10261878, is intergenic and located 39 kb from a microRNA-encoding gene (*MIR148A*), which has been found to be significantly upregulated during adipogenesis[30], as well as in human adipocytes[31]. In addition, human miR-148a has been shown to regulate *CCKBR* (encoding cholecystokinin B receptor), which has been reported to have a regulatory role in the control of food intake[32]. The next closest gene (241 kb from rs10261878) is *NFE2L3* (encoding the nuclear factor (erythroid-derived 2)-like 3), a transcription factor that binds to antioxidant response elements of target genes and seems to have a role in differentiation, inflammation and carcinogenesis[33].

The most significant SNP at chromosome 6q16 (rs974417) is intronic in *KLHL32* (encoding kelch-like 32). Kelch-like genes have propeller domains that bind substrate proteins, promoting substrate ubiquitination, which modulates protein function. We also detected evidence of recent positive selection in and downstream of *KLHL32* (**Supplementary Figs. 6–9** and **Supplementary Note**).

In the largest GWAS meta-analysis of African-ancestry populations so far, we identified two new loci and one highly suggestive locus influencing BMI. The most informative SNPs in each of these three loci explain 0.10% of the variance in BMI in African-ancestry populations compared to 0.05% in Europeans and 0.03% in Asians (**Table 1** and **Supplementary Table 6**). Using the most significant ancestry-specific markers from each locus, the 36 known BMI loci explain 1.30% of the variance in BMI in men and women of African ancestry compared with 1.67% and 1.25% in European and Asian-ancestry populations, respectively (**Supplementary Tables 12** and **13**). We provide evidence for a shared genetic influence on BMI across populations, as we found directionally consistent associations with the majority of known BMI risk variants. This observation suggests that the biologically functional alleles are ancient and probably arose before migrations out of Africa. In addition, we were able to refine the window of association of some of the previously established BMI loci, which may eventually help identify the biologically functional variant(s). In this study we did not identify common variants for BMI that are likely to contribute to population differences in the prevalence of obesity. The ability to map new loci and replicate signals at established loci found in other populations reflects differences in allele frequency and effect size, which are influenced by population differences in recent demographic history and LD with the functional variant, as well as genetic and environmental modifying factors. Further studies will be needed to test the biologically functional alleles at the known loci, as well as the contribution of less common variation that have not yet been adequately surveyed by genome-wide SNP arrays. Taken together these findings demonstrate the importance of conducting genetic studies in diverse populations to identify new susceptibility loci for common traits.

METHODS

Methods and any associated references are available in the online version of the paper.

Note: Supplementary information is available in the online version of the paper.

AUTHOR CONTRIBUTIONS
Design and/or management of the individual studies: A.A., A.A.A., C.B.A., C.I.A., D.K.A., L.A., M.C.A., M.A.A., S.A., C.H.B., D.M.B., D.W.B., E.P.B., E.V.B., G.B., I.B.B., J.P.B., L.B., S.I.B., W.J.B., C.S.C., G. Casey, G.K.C., J.C., L.C., M.C., N.E.C., Q.C., R.S.C., S.J.C., J.D., P.D., R.W.D., S.L.D.-H., M.K.E., T.L.E., C.F., J.K.F., E.M.G., P.J.G., S.F.A.G., A.H., A.J.M.H., B.E.H., B.V.H., C.A.H., C.C.H., D.H., H.H., K.J.H., J.J.H., J.N.H., V.J.H., S.A.I., E.M.J., J.M.J., C.K., D.L.K., E.A.K., E.K.K., L.N.K., L.H.K., R.A.K., S.J.K., S. Kolb, L.L.M., A.M.L., R.J.F.L., S.L., Yongmei Liu, A.B.M., B.M., K.R.M., R.C.M., T.H.M., J.H.M., J.C.M., I.M.-B., K.E.N., M.C.Y.N., S.N., C.N.-D., U.N., B.N., K.L.N., T.O.O., O.O., O.I.O., B.P., U.P., B.M.P., C.A.P., G.J.P., J.R.P., M.F.P., P.A.P., S.R.P., E.A.R.-N., B.A.R., C.N.R., S.R., J.L.R.-G., A.B.S., A.G.S., J.L.S., L.B.S., P.J.S., S.B.S., S.W.-S., M.R.S., M.M.S., I.J.S., S.S.S., H.T., M.J.T., M.A.T., M.V., J.S.W., X.W., J.K.W., S.M.W., L.K.W., M.W., J.J.Y., N.A.Z., R.G.Z., W. Zheng, A.B.Z., K.A.Z., Y.Z. and X.Z.

Genotyping: A.B., U.B., S.J.C., Y.-D.I.C., D.D., T.L.E., S.F.A.G., X.G., D.G.H., J.N.H., T.D.H., T. Haritunians, K.C.J., Yongmei Liu, Y. Lu, W.M., R.N., J.R.P., N.D.P., S.B.S. and D.J.V.D.B.

Phenotyping: A.A.A., D.K.A., M.A.A., E.P.B., R.S.C., E.D., B.I.F., O.G., S.F.A.G., J.N.H., T. Haritunians, K.C.J., A.K., C.K., E.K.K., S.L., J.E.M., M.N., R.N., A.O., H.O.-B., B.M.P., J.R.P., S.R.P., C.N.R., E.R., S.R., B.S., D.S., L.S., B.O.T. and T.R.Y.

Statistical methods and data analysis: A.A.A., D.K.A., L.F.B., C.W.K.C., G.K.C., G. Casey, N.E.C., W.-M.C., G.A.C., Y.-D.I.C., J.D., P.D., T.L.E., C.F., M.F.F., J.P.B., E.M.G., M.G., O.G., X.G., C.A.H., M.R.I., A.K., B.J.K., C.K., E.K.K., S.J.K., C.D.L., G. Lettre, G. Li, H.L., K.L., L.A.L., R.J.F.L., V.L., Yongmei Liu, Youfang Liu, Y. Lu, B.M., K.L.M., Y.A.M., A.N., K.E.N., M.A.N., M.C.Y.N., C.P., J.R.P., E.A.R.-N., S.K.R., B.P., A.P.R., L.J.R.-T., D.A.S., E.K.S., E.E.S., Y.V.S., B.O.T., K.C.T., D.R.V.E., M.K.W., Z.W., L.K.W., T.W.W., L.R.Y., J.Z., J.H.Z., N.A.Z., J.M.Z., W. Zhao, the NABEC Consortium, the UKBEC Consortium, the BioBank Japan Project and the AGEN Consortium.

Writing group: G.K.C., T.L.E., M.G., B.E.H., J.N.H., R.J.F.L., C.A.H., L.A.L., K.L.M., K.E.N., M.C.Y.N., C.P., G.J.P., A.P.R. and K.C.T.

Critical review of the manuscript: A.A.A., A.A., C.B.A., C.I.A., D.K.A., L.A., M.A.A., M.C.A., S.A., A.B., C.H.B., D.M.B., D.W.B., E.P.B., E.V.B., G.B., I.B.B., J.P.B., L.F.B., L.B., S.I.B., U.B., W.J.B., C.W.K.C., C.S.C., F.C., G.A.C., G.K.C., G. Casey, G. Chen, J.C., L.C., M.C., N.E.C., Q.C., R.S.C., S.J.C., W.-M.C., Y.-D.I.C., D.D., E.D., J.D., P.D., R.W.D., S.L.D.-H., M.K.E., T.L.E., C.F., J.K.F., M.F.F., B.I.F., Y.F., E.M.G., G.S.G., M.G., O.G., P.J.G., S.F.A.G., W.T.G., X.G., A.J.M.H., A.H., B.E.H., B.V.H., C.A.H., C.C.H., D.G.H., D.H., H.H., J.J.H., J.N.H., K.J.H., T.D.H., T. Haritunians, T. Harris, V.J.H., J.H.M., M.R.I., S.A.I., E.M.J., J.M.J., K.C.J., A.K., B.J.K., C.K., D.L.K., E.A.K., E.K.K., L.N.K., L.H.K., R.A.K., S.J.K., S.L.R.K., S. Kolb, S. Ketkar, A.M.L., C.D.L., G. Lettre, G. Li, H.L., K.L., L.A.L., L.L., M.C.L., R.J.F.L., S.L., V.L., Yongmei Liu, Youfang Liu, Y. Lu, A.B.M., B.M., J.C.M., J.E.M., L.H.M., K.L.M., K.R.M., R.C.M., T.H.M., W.M., Y.A.M., I.M.-B., A.N., B.N., K.E.N., K.L.N., M.A.N., M.C.Y.N., M.N., R.N., S.N., U.N., C.N.-D., O.I.O., O.O., T.O.O., A.O., H.O.-B., B.M.P., B.P., C.A.P., C.P., G.J.P., J.R.P., M.F.P., N.D.P., P.A.P., S.R.P., U.P., A.P.R., B.A.R., C.N.R., E.R., S.K.R., S.R., J.L.R.-G., E.A.R.-N., L.J.R.-T., A.B.S., A.G.S.,

B.S., D.A.S., D.S., E.K.S., E.E.S., I.J.S., J.L.S., L.B.S., L.S., M.M.S., M.R.S., P.J.S., S.B.S., S.S.S., Y.V.S., B.O.T., K.C.T., M.A.T., H.T., M.J.T., M.V., D.J.V.D.B., D.R.V.E., J.K.W., M.W., S.M.W., S.-Y.W., S.W.-S., T.W.W., X.W., Z.W., L.K.W., J.S.W., M.K.W., J.J.Y., L.R.Y., T.R.Y., A.B.Z., J.Z., J.M.Z., J.H.Z., K.A.Z., N.A.Z., R.G.Z., W. Zhao, W Zheng, X.Z. and Y.Z.

1. Flegal, K.M., Carroll, M.D., Kit, B.K. & Ogden, C.L. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. *J. Am. Med. Assoc.* **307**, 491–497 (2012).
2. Bradfield, J.P. *et al.* A genome-wide association meta-analysis identifies new childhood obesity loci. *Nat. Genet.* **44**, 526–531 (2012).
3. Thorleifsson, G. *et al.* Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat. Genet.* **41**, 18–24 (2009).
4. Frayling, T.M. *et al.* A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* **316**, 889–894 (2007).
5. Scuteri, A. *et al.* Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS Genet.* **3**, e115 (2007).
6. Loos, R.J.F. *et al.* Common variants near MC4R are associated with fat mass, weight and risk of obesity. *Nat. Genet.* **40**, 768–775 (2008).
7. Speliotes, E.K. *et al.* Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat. Genet.* **42**, 937–948 (2010).
8. Willer, C.J. *et al.* Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nat. Genet.* **41**, 25–34 (2009).
9. Okada, Y. *et al.* Common variants at CDKAL1 and KLF9 are associated with body mass index in east Asian populations. *Nat. Genet.* **44**, 302–306 (2012).
10. Wen, W. *et al.* Meta-analysis identifies common variants associated with body mass index in east Asians. *Nat. Genet.* **44**, 307–311 (2012).
11. Chambers, J.C. *et al.* Common genetic variation near MC4R is associated with waist circumference and insulin resistance. *Nat. Genet.* **40**, 716–718 (2008).
12. Meyre, D. *et al.* Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. *Nat. Genet.* **41**, 157–159 (2009).
13. Scherag, A. *et al.* Two new loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and german study groups. *PLoS Genet.* **6**, e1000916 (2010).
14. Ng, M.C. *et al.* Genome-wide association of BMI in African Americans. *Obesity (Silver Spring)* **20**, 622–627 (2012).
15. Kang, S.J. *et al.* Genome-wide association of anthropometric traits in African- and African-derived populations. *Hum. Mol. Genet.* **19**, 2725–2738 (2010).
16. Shifman, S., Kuypers, J., Kokoris, M., Yakir, B. & Darvasi, A. Linkage disequilibrium patterns of the human genome across populations. *Hum. Mol. Genet.* **12**, 771–776 (2003).
17. Campbell, M.C. & Tishkoff, S.A. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. *Annu. Rev. Genomics Hum. Genet.* **9**, 403–433 (2008).
18. N'Diaye, A. *et al.* Identification, replication, and fine-mapping of loci associated with adult height in individuals of african ancestry. *PLoS Genet.* **7**, e1002298 (2011).
19. Heid, I.M. *et al.* Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. *Nat. Genet.* **42**, 949–960 (2010).
20. Teslovich, T.M. *et al.* Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* **466**, 707–713 (2010).
21. Dupuis, J. *et al.* New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* **42**, 105–116 (2010).
22. Saxena, R. *et al.* Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. *Nat. Genet.* **42**, 142–148 (2010).
23. Voight, B.F. *et al.* Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat. Genet.* **42**, 579–589 (2010).
24. Ehret, G.B. *et al.* Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* **478**, 103–109 (2011).
25. Nalls, M.A. *et al.* Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet* **377**, 641–649 (2011).
26. Hernandez, D.G. *et al.* Distinct DNA methylation changes highly correlated with chronological age in the human brain. *Hum. Mol. Genet.* **20**, 1164–1172 (2011).
27. Zhong, H., Yang, X., Kaplan, L.M., Molony, C. & Schadt, E.E. Integrating pathway analysis and genetics of gene expression for genome-wide association studies. *Am. J. Hum. Genet.* **86**, 581–591 (2010).
28. Myers, A.J. *et al.* A survey of genetic human cortical gene expression. *Nat. Genet.* **39**, 1494–1499 (2007).
29. Cheng, L. *et al.* Characterization of a novel human UDP-GalNAc transferase, pp-GalNAc-T10. *FEBS Lett.* **531**, 115–121 (2002).
30. Xie, H., Lim, B. & Lodish, H.F. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. *Diabetes* **58**, 1050–1057 (2009).
31. Ortega, F.J. *et al.* MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. *PLoS ONE* **5**, e9022 (2010).
32. Clerc, P. *et al.* Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice. *Endocrinology* **148**, 1039–1049 (2007).
33. Chevillard, G. & Blank, V. NFE2L3 (NRF3): the Cinderella of the Cap'n'Collar transcription factors. *Cell Mol. Life Sci.* **68**, 3337–3348 (2011).

Keri L Monda[1,2,156], Gary K Chen[3,156], Kira C Taylor[2,4,156], Cameron Palmer[5–7,156], Todd L Edwards[8,156], Leslie A Lange[9], Maggie C Y Ng[10,11], Adebowale A Adeyemo[12], Matthew A Allison[13], Lawrence F Bielak[14], Guanjie Chen[12], Mariaelisa Graff[2], Marguerite R Irvin[15], Suhn K Rhie[3,16], Guo Li[17], Yongmei Liu[18], Youfang Liu[19], Yingchang Lu[20], Michael A Nalls[21], Yan V Sun[22], Mary K Wojczynski[23], Lisa R Yanek[24], Melinda C Aldrich[25–27], Adeyinka Ademola[28], Christopher I Amos[29,30], Elisa V Bandera[31], Cathryn H Bock[32], Angela Britton[21], Ulrich Broeckel[33], Quiyin Cai[25,26], Neil E Caporaso[34], Chris S Carlson[35], John Carpten[36], Graham Casey[3,16], Wei-Min Chen[37], Fang Chen[37], Yii-Der I Chen[38], Charleston W K Chiang[39], Gerhard A Coetzee[3,16,40], Ellen Demerath[41], Sandra L Deming-Halverson[25,26], Ryan W Driver[42], Patricia Dubbert[43–45], Mary F Feitosa[23], Ye Feng[3], Barry I Freedman[46], Elizabeth M Gillanders[47], Omri Gottesman[20], Xiuqing Guo[38], Talin Haritunians[38], Tamara Harris[48], Curtis C Harris[49], Anselm J M Hennis[50–53], Dena G Hernandez[21], Lorna H McNeill[54,55], Timothy D Howard[11], Barbara V Howard[56,57], Virginia J Howard[15], Karen C Johnson[58], Sun J Kang[59], Brendan J Keating[60], Suzanne Kolb[35], Lewis H Kuller[61], Abdullah Kutlar[62], Carl D Langefeld[63], Guillaume Lettre[64], Kurt Lohman[63], Vaneet Lotay[20], Helen Lyon[65,66], JoAnn E Manson[67], William Maixner[68], Yan A Meng[69], Kristine R Monroe[3], Imran Morhason-Bello[70], Adam B Murphy[71], Josyf C Mychaleckyj[37], Rajiv Nadukuru[20], Katherine L Nathanson[72], Uma Nayak[37], Amidou N'Diaye[65], Barbara Nemesure[50], Suh-Yuh Wu[50], M Cristina Leske[50], Christine Neslund-Dudas[73], Marian Neuhouser[74], Sarah Nyante[75,76], Heather Ochs-Balcom[77], Adesola Ogunniyi[78], Temidayo O Ogundiran[28], Oladosu Ojengbede[70], Olufunmilayo I Olopade[79], Julie R Palmer[80], Edward A Ruiz-Narvaez[80], Nicholette D Palmer[10,11], Michael F Press[81], Evandine Rampersaud[82], Laura J Rasmussen-Torvik[83], Jorge L Rodriguez-Gil[84,85], Babatunde Salako[78], Eric E Schadt[86,87], Ann G Schwartz[32], Daniel A Shriner[10], David Siscovick[17,88],

Shad B Smith[68], Sylvia Wassertheil-Smoller[89], Elizabeth K Speliotes[90–93], Margaret R Spitz[94], Lara Sucheston[95], Herman Taylor[96], Bamidele O Tayo[97], Margaret A Tucker[34], David J Van Den Berg[3,16], Digna R Velez Edwards[98,99], Zhaoming Wang[100], John K Wiencke[101,102], Thomas W Winkler[20,103], John S Witte[104], Margaret Wrensch[101,102], Xifeng Wu[29], James J Yang[73], Albert M Levin[73], Taylor R Young[93], Neil A Zakai[105], Mary Cushman[105], Krista A Zanetti[47,49], Jing Hua Zhao[106], Wei Zhao[107], Yonglan Zheng[79], Jie Zhou[10], Regina G Ziegler[34], Joseph M Zmuda[61], Jyotika K Fernandes[108], Gary S Gilkeson[108], Diane L Kamen[108], Kelly J Hunt[108], Ida J Spruill[109], Christine B Ambrosone[95], Stefan Ambs[49], Donna K Arnett[15], Larry Atwood[110,155], Diane M Becker[24], Sonja I Berndt[34], Leslie Bernstein[111], William J Blot[25,26,112], Ingrid B Borecki[23], Erwin P Bottinger[20], Donald W Bowden[10,11,46], Gregory Burke[113], Stephen J Chanock[34], Richard S Cooper[97], Jingzhong Ding[114], David Duggan[36], Michele K Evans[115], Caroline Fox[116–118], W Timothy Garvey[119], Jonathan P Bradfield[120,121], Hakon Hakonarson[120–123], Struan F A Grant[120–123], Ann Hsing[124–126], Lisa Chu[126], Jennifer J Hu[84,85], Dezheng Huo[127], Sue A Ingles[3], Esther M John[124–126], Joanne M Jordan[19], Edmond K Kabagambe[25], Sharon L R Kardia[107], Rick A Kittles[128], Phyllis J Goodman[129], Eric A Klein[130], Laurence N Kolonel[131], Loic Le Marchand[131], Simin Liu[132], Barbara McKnight[17,133], Robert C Millikan[75,76,155], Thomas H Mosley[96], Badri Padhukasahasram[134], L Keoki Williams[134,135], Sanjay R Patel[136], Ulrike Peters[35], Curtis A Pettaway[137], Patricia A Peyser[107], Bruce M Psaty[17,138,139], Susan Redline[140], Charles N Rotimi[12], Benjamin A Rybicki[73], Michèle M Sale[141–143], Pamela J Schreiner[41], Lisa B Signorello[144], Andrew B Singleton[21], Janet L Stanford[35], Sara S Strom[29], Michael J Thun[42], Mara Vitolins[113], Wei Zheng[25,26], Jason H Moore[145–147], Scott M Williams[145,146], Shamika Ketkar[148], Xiaofeng Zhu[149], Alan B Zonderman[150], NABEC Consortium[151], UKBEC Consortium[151], BioBank Japan Project[151], AGEN Consortium[151], Charles Kooperberg[35], George J Papanicolaou[152], Brian E Henderson[3,16], Alex P Reiner[35], Joel N Hirschhorn[5–7,39], Ruth J F Loos[20,106,153,154], Kari E North[2,157] & Christopher A Haiman[3,16,157]

[1]The Center for Observational Research, Amgen, Inc. Thousand Oaks, California, USA. [2]Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. [3]Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [4]Department of Epidemiology and Population Health, University of Louisville, Louisville, Kentucky, USA. [5]Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [6]Division of Genetics, Children's Hospital, Boston, Massachusetts, USA. [7]Division of Endocrinology, Children's Hospital, Boston, Massachusetts, USA. [8]Center for Human Genetics Research, Vanderbilt Epidemiology Center, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA. [9]Department of Genetics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA. [10]Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. [11]Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. [12]Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA. [13]Department of Family and Preventive Medicine, University of California San Diego, La Jolla, California, USA. [14]Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA. [15]Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA. [16]Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA. [17]Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA. [18]Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. [19]Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. [20]The Charles Bronfman Institute of Personalized Medicine, The Icahn School of Medicine at Mount Sinai, New York, New York, USA. [21]Laboratory of Neurogenetics, National Institute on Aging (NIA), NIH, Bethesda, Maryland, USA. [22]Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. [23]Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA. [24]Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. [25]Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. [26]The Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. [27]Department of Thoracic Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. [28]Department of Surgery, College of Medicine, University of Ibadan, Ibadan, Nigeria. [29]Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [30]Department of Family and Community Medicine, Geissel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA. [31]The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. [32]Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA. [33]Department of Pediatrics, Section of Genomic Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. [34]Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA. [35]Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. [36]The Translational Genomics Research Institute, Phoenix, Arizona, USA. [37]Center for Public Health Genomics, Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA. [38]Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA. [39]Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. [40]Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [41]Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA. [42]Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA. [43]South Central VA Mental Illness, Research and Clinical Center, Little Rock, Arkansas, USA. [44]VA Geriatric Research, Education and Clinical Center, Little Rock, Arkansas, USA. [45]Division of Health Services Research, Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. [46]Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. [47]Division of Cancer Control and Population Sciences, NCI, NIH, Bethesda, Maryland, USA. [48]Laboratory of Epidemiology and Population Science, NIA, NIH, Bethesda, Maryland, USA. [49]Laboratory of Human Carcinogenesis, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA. [50]Department of Preventive Medicine, Stony Brook University, Stony Brook, New York, USA. [51]Chronic Disease Research Centre, University of the West Indies, Bridgetown, Barbados. [52]Faculty of Medical Sciences, University of the West Indies, Bridgetown, Barbados. [53]Ministry of Health, Bridgetown, Barbados. [54]Department of Health Disparities Research, Division of the Office of the Vice President (OVP), Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [55]Center for Community-Engaged Translational Research, Duncan Family Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [56]MedStar Health Research Institute, Washington DC, USA. [57]Georgetown-Howard Universities Center for Clinical and Translational Sciences, Washington, DC, USA. [58]Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA. [59]Henri Begleiter Neurodynamics Laboratory, Department of

Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, New York, USA. [60]Institute of Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. [61]Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. [62]Sickle Cell Center, Department of Medicine, Georgia Health Sciences University, Augusta, Georgia, USA. [63]Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. [64]Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada. [65]Program in Genomics and Endocrinology, Division of Genetics, Children's Hospital, Boston, Massachusetts, USA. [66]Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA. [67]Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. [68]Regional Center for Neurosensory Disorders, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. [69]Broad Institute of Harvard and MIT, Metabolic Disease Initiative, Cambridge, Massachusetts, USA. [70]Center for Population and Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Nigeria. [71]Department of Urology, Northwestern University, Chicago, Illinois, USA. [72]Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. [73]Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan, USA. [74]Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. [75]Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA. [76]Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA. [77]Department of Social and Preventive Medicine, University at Buffalo, Buffalo, New York, USA. [78]Department of Medicine, University of Ibadan, Ibadan, Nigeria. [79]Department of Medicine, University of Chicago, Chicago, Illinois, USA. [80]Slone Epidemiology Center at Boston University, Boston, Massachusetts, USA. [81]Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [82]Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, Florida, USA. [83]Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. [84]Department of Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, Florida, USA. [85]Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA. [86]Department of Genetics and Genomic Sciences, The Icahn School of Medicine at Mount Sinai, New York, New York, USA. [87]Icahn Institute for Genomics and Multiscale Biology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA. [88]Department of Epidemiology, University of Washington, Seattle, Washington, USA. [89]Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA. [90]Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA. [91]Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA. [92]Division of Gastroenterology. Massachusetts General Hospital, Boston, Massachusetts, USA. [93]The Broad Institute, Cambridge, Massachusetts, USA. [94]Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA. [95]Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA. [96]Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA. [97]Department of Preventive Medicine and Epidemiology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA. [98]Center for Human Genetics Research, Vanderbilt Epidemiology Center, Vanderbilt University, Nashville, Tennessee, USA. [99]Vanderbilt Epidemiology Center, Department of Obstetrics and Gynecology, Vanderbilt University, Nashville, Tennessee, USA. [100]Core Genotype Facility, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, USA. [101]Institute for Human Genetics, University of California San Francisco, San Francisco, California, USA. [102]Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA. [103]Department of Genetic Epidemiology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany. [104]Department of Epidemiology and Biostatistics, Institute for Human Genetics, University of California, San Francisco, San Francisco, California, USA. [105]Department of Medicine, University of Vermont College of Medicine, Burlington, Vermont, USA. [106]Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. [107]Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA. [108]Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. [109]College of Nursing, Medical University of South Carolina, Charleston, South Carolina, USA. [110]Framingham Heart Study, Boston University School of Medicine, Boston, Massachusetts, USA. [111]Division of Cancer Etiology, Department of Population Science, Beckman Research Institute, City of Hope, Duarte. California, USA. [112]International Epidemiology Institute, Rockville, Maryland, USA. [113]Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. [114]Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. [115]Health Disparities Research Section, Laboratory of Population Science, NIA, NIH, Baltimore, Maryland, USA. [116]National Heart, Lung and Blood Institute (NHLBI) Framingham Heart Study, Framingham, Massachusetts, USA. [117]NHLBI Center for Population Studies, Framingham, Massachusetts, USA. [118]Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. [119]Department of Nutrition Sciences, University of Alabama at Birmingham and the Birmingham VA Medical Center, Birmingham, Alabama, USA. [120]The Center for Applied Genomics, The Children's Hospital of Philadelphia Research Institute, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [121]Division of Human Genetics, The Children's Hospital of Philadelphia Research Institute, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. [122]Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. [123]Institute of Diabetes, Obesity and Metabolism, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. [124]Cancer Prevention Institute of California, Fremont, California, USA. [125]Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA. [126]Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA. [127]Department of Health Studies, University of Chicago, Chicago, Illinois, USA. [128]Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA. [129]Southwest Oncology Group (SWOG) Statistical Center, Seattle, Washington, USA. [130]Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. [131]Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA. [132]Department of Epidemiology, School of Public Health, University of California at Los Angeles, Los Angeles, California, USA. [133]Department of Biostatistics, University of Washington, Seattle, Washington, USA. [134]Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan, USA. [135]Department of Internal Medicine, Henry Ford Health System, Detroit, Michigan, USA. [136]Division of Sleep Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. [137]Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [138]Department of Epidemiology and Health Services, University of Washington, Seattle, Washington, USA. [139]Group Health Research Institute, Group Health Cooperative, Seattle, Washington, USA. [140]Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. [141]Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA. [142]Department of Medicine, University of Virginia, Charlottesville, Virginia, USA. [143]Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia, USA. [144]Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. [145]Institute for Quantitative Biomedical Sciences, The Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA. [146]Department of Genetics, The Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA. [147]Department of Community and Family Medicine, The Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA. [148]Division of Biology and Biomedical Sciences, Human and Statistical Genetics Program, Washington University, St. Louis, Missouri, USA. [149]Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA. [150]Behavioral Epidemiology Section, Laboratory of Population Science, NIA, NIH, Baltimore, Maryland, USA. [151]A list of contributing members appears in the **Supplementary Note**. [152]Division of Prevention and Population Sciences, NHLBI, NIH, Bethesda, Maryland, USA. [153]The Genetics of Obesity and Related Metabolic Traits Program, The Icahn School of Medicine at Mount Sinai, New York, New York, USA. [154]The Mindich Child Health and Development Institute, The Icahn School of Medicine at Mount Sinai, New York, New York, USA. [155]Deceased. [156]These authors contributed equally to this work. [157]These authors jointly directed this work. Correspondence should be addressed to K.E.N. (kari_north@unc.edu) or C.A.H. (haiman@usc.edu).

ONLINE METHODS

Study design. We used a three-stage design consisting of a GWAS meta-analysis (stage 1), a follow-up of 1,500 SNPs (stage 2) and a focused follow-up of the three new loci (stage 3). Stage 1 included results from 36 GWAS of 39,144 men and women of African ancestry (37,956 African American and 1,188 African; **Supplementary Table 1**). We took forward the 1,500 most significantly associated SNPs ($P < 0.0003$) for examination in 6,817 additional men and women of African ancestry from seven GWAS (stage 2, all African American). The three SNPs that reached genome-wide significance ($P < 5 \times 10^{-8}$) after the meta-analysis of the results from stages 1 and 2 were taken forward for further confirmation in 25,451 additional African-ancestry subjects from 12 studies. All participants in these studies provided written informed consent for the research, and approval for the study was obtained from the ethics review boards at all participating institutions. A description of each participating study as well as details regarding the measurement and collection of height and weight data are provided in the **Supplementary Note**.

Genotyping and quality control. Genotyping in each study was conducted using Illumina or Affymetrix genome-wide SNP arrays. The size of each study ranged from 50 to 8,421 individuals. The details of the array, genotyping quality-control procedures and sample exclusions for each study that contributed data are listed in **Supplementary Tables 1** and **2**.

Statistical analyses. In all GWAS, imputation to phased haplotype data from the founders of the CEU and YRI HapMap phase 2 samples (build 21) was performed using MACH[34], IMPUTE2 (ref. 35) or BEAGLE[36]. SNPs with lower imputation quality scores ($r^2 < 0.3$) (**Supplementary Table 2**) as well as SNPs with a small number of allele counts after stratifying by sex and case-control status were excluded from the analyses. Local ancestry, defined as the number of European chromosomes (continuous between 0 and 2), was estimated for the majority of the stage 1 African-ancestry studies (**Supplementary Table 8**) using HAPMIX[37]. To evaluate the effect of admixture on the allele distribution between the African and European segments, we stratified the analysis of each variant by local ancestry at each locus (**Supplementary Table 9**).

Stage 1. Genome-wide association analyses were performed by each of the participating studies. BMI was regressed on age, age squared and study site (if needed) to obtain residuals, separately by sex and case-control status, if needed. Residuals were inverse-normally transformed to obtain a standard normal distribution with a mean of 0 and an s.d. of 1. For studies with unrelated subjects, each SNP was tested for additive association with BMI by regressing the transformed residuals on the number of copies of the SNP effect allele adjusting for population structure as measured by the first eigenvectors calculated for each study. Analyses were stratified by sex and case-control status (if needed). For studies that included related individuals, family based association tests were conducted that took into consideration the genetic relationships among the individuals. Study-specific λ values ranged from 0.95 to 1.08 (**Supplementary Table 2**). We applied genomic control in the stage 1 analysis (that is, we divided by the median of all χ^2 statistics for each study) to eliminate any remaining overdispersion before combining the GWAS in the meta-analysis. In stage 1, we conducted a fixed-effect meta-analysis using the inverse variance–weighted method implemented in the program METAL[38]. We performed a second genomic control correction of the stage 1 meta-analysis results ($\lambda = 1.136$) before selecting SNPs for follow-up.

Stages 2 and 3. The 1,500 most significant SNPs from stage 1 were examined in an additional 6,817 individuals, with each SNP being analyzed as described for stage 1 and meta-analyzed using the inverse-variance method using METAL. As in stage 1, each SNP was tested for association with BMI by regressing the transformed residuals on the number of copies of the SNP effect allele adjusting for population structure as measured by the first ten eigenvectors calculated for each study. Further testing of the three new variants was conducted in an additional 25,451 individuals (stage 3). Results from all stages were meta-analyzed using the inverse-variance method in METAL.

Examination in individuals of European ancestry. We also examined the 1,500 most statistically significant SNPs from stage 1 in the GIANT consortium

($n = 123,706$ individuals of European ancestry)[7]. Of these, 1,390 were genotyped or imputed in GIANT, and 1,328 had data for $n > 50,000$ individuals and MAF > 1%. We conducted a meta-analysis of stages 1, 2 and 3 plus GIANT in the same manner as described above. The three new variants were also examined in the AGEN and RIKEN consortia[9,10] and the Pediatric Research Consortium (PeRC) (**Supplementary Note**).

Estimation of variance explained. The total fraction of variance explained was calculated using the formula $2f(1 - f) \times a^2$, where f is the frequency of the variant, and a is the additive effect of the variant[3]. When calculating percentage variance explained in the African-ancestry sample for the previously discovered BMI variants that were not genome-wide significant in stage 1, we used data from the stage 1 sample; for those that were genome-wide significant in stage 1, we used data from the stage 2 sample; and for the new BMI variants, we used data from the combined stage 2 and 3 samples to avoid inflating the estimates as a result of winner's curse. When summing percentage variance explained for the 36 previously discovered BMI variants (**Supplementary Table 12**), we used the more informative SNP discovered through fine mapping at the seven loci (**Supplementary Table 13**). However, for these seven variants, the stage 1 results were used, and estimates may be biased; stage 2 and 3 studies only participated in the look-up of the top SNPs from the preceding stages.

Bioinformatic analysis of the new BMI loci. In an attempt to identify functionality in noncoding regions at the three loci, we used FunciSNP version 0.99 (ref. 39), which systematically integrates the 1,000 Genomes SNP data (1KGP, April 2012) with chromatin features of interest. To capture regulatory elements, we used 73 different chromatin features generated by next-generation sequencing technologies in brain and adipose tissues from the NIH Epigenomics Roadmap[40], as well as known DNaseI hypersensitive locations, formaldehyde-assisted isolation of regulatory elements sequencing (FAIRE-seq) peaks and CTCF binding sites from more than 100 different cell types, which were collected from the ENCODE data[41]. All SNPs with $r^2 > 0.5$ with each index SNP in the 1KGP AFR populations in a 1-Mb window around each index variant were cataloged. We used the UCSC Genome Browser (http://genome.ucsc.edu/) to illustrate the correlated SNPs that overlap chromatin features from these tissues, as well as chromatin features from seven cell lines used in the ENCODE Project (**Supplementary Fig. 5a–c**). The results from these analyses are provided in **Supplementary Tables 16–19**.

eQTL analyses. *Liver, subcutaneous fat and omental fat tissue.* The determination of eQTLs in liver, subcutaneous fat and omental fat tissue have been described in detail previously[27]. In brief, liver, subcutaneous fat and omental fat tissue were obtained from patients of European ancestry who underwent bariatric surgery. Expression of a total of 39,280 oligonucleotide probes targeting transcripts representing 34,266 known and predicted genes was assessed. All patients were genotyped on a genome-wide SNP array, and association between SNPs and gene expression data was adjusted for age, race, gender and surgery year using linear regression. Results are presented in **Supplementary Table 14** and **Supplementary Figure 4**.

Brain cortical tissue. We examined the *cis* associations (defined as genes within 1 Mb) between each of the BMI-associated SNPs and expression of nearby genes in brain (cortical tissue)[28]. The eQTL analyses have been described in detail previously (Gene Expression Omnibus (GEO) database GSE8919)[28]. In brief, DNA and RNA of neuropathologically normal cortical brain samples of 193 individuals (average age (range), 81 (65–100) years) of European ancestry were isolated and genotyped for a genome-wide SNP array, and HapMap genotypes were imputed. RNA expression was assessed for 24,357 transcripts, of which 14,078 transcripts met the quality-control criteria. Association analyses between SNPs and expression data assumed an additive model and were adjusted for sex and age at death. Results are presented in **Supplementary Table 14** and **Supplementary Figure 4**.

Association testing of previously established BMI loci. To characterize alleles that might better represent the biologically functional variant at the 36 previously discovered BMI loci, we searched for LD proxies among individuals

of African ancestry. Using HapMap data (CEU or JPT/CHB) to estimate LD, we identified all SNPs that were correlated ($r^2 \geq 0.4$) with the index SNP (within 250 kb or larger to include a nearby gene). Next we tested these SNPs for association with BMI in the stage 1 African-ancestry sample. We applied a locus-specific significance criterion, α, which accounts for multiple testing (the number of tag SNPs in the HapMap YRI population that capture (at $r^2 \geq 0.8$) all common SNPs (with MAF ≥ 0.05) correlated with the index signal in the HapMap CEU or JPT/CHB populations). This α level does not account for the number of regions evaluated and reflects a balance between the need to correct for multiple comparisons and the prior knowledge that each region harbors a risk variant for BMI. We also looked for new independent associations, focusing on the genotyped and imputed SNPs that were uncorrelated with the index signal in the initial GWAS populations ($r^2 < 0.2$). We applied a Bonferroni correction for defining new associations as significant in each region as 0.05 divided by the total number of tags needed to capture (at $r^2 \geq 0.8$) all common risk alleles across all risk regions in the YRI population ($\alpha = 6.7 \times 10^{-6}$).

Detection of recent positive selection in Africans and Europeans at a new BMI locus. We evaluated the evidence for recent positive selection at our new loci using several statistical techniques, the BioVU African-American GWAS data and data from the International HapMap Project and the Human Genome Diversity Project (HGDP). We compared adjusted allele frequencies among BioVU and HapMap phase 3 participants from the west African Yoruban (YRI) and east African Luhya (LWK) populations using Treeselect[42]. The LWK sample is differentiated from the YRI sample and samples of African Americans[43]. Allele frequencies in the African-American sample were adjusted by subtracting the expected contribution of European alleles, where p_{AA} is the allele frequency in African Americans obtained from experimental data, p_{EA} is the allele frequency in Europeans obtained from HapMap, p_{AF} is the estimated allele frequency in African founders and α is the average proportion of ancestry from Europeans, or 0.2. The adjustment is then performed by solving the following expression for p_{AF}:

$$p_{AF} = \frac{p_{AA} - \alpha p_{EA}}{(1 - \alpha)}$$

We also evaluated the HapMap phase 2 and HGDP data with the integrated haplotype score (iHS)[44] and Haplotter and the crosspopulation-extended haplotype homozygosity (XP-EHH) statistic using the HGDP selection browser[45,46]. We also evaluated the BioVU data using 5,000 random autosomal SNPs with STRUCTURE v2.3.3, and on average, the participants were 20.7% European and 79.3% of African ancestry[47,48].

We observed evidence for recent selection near *KLHL32* within the YRI HapMap data using iHS (**Supplementary Fig. 4**) and in the HGPD African participants (**Supplementary Fig. 5a–d**). Nominal evidence of selection was observed within the YRI and African-American populations using the Treeselect statistic with the transcription factor binding–site SNP rs1206131 ($P = 0.003$ in

the African Americans and $P = 0.005$ in YRI) and at the SNP rs9387284 ($P = 0.004$ in the YRI and $P = 0.026$ in the African Americans) (**Supplementary Fig. 6a,b**). The Treeselect method also demonstrated a significant allele frequency differentiation between African and African-ancestry populations (F_{st} ~0.01) at the transcription factor binding–site SNP rs1206131. rs1206131 is the most significant SNP for this test in the region ±400 kb. The test from the African-American branch of the tree was slightly less significant at rs1206131, and the most significant SNP was downstream, which is also under the iHS and XP-EHH peaks from Africans in the HGDP and HapMap data. The graph of HGDP allele frequencies at this SNP shows that the ancestral T allele has increased frequencies throughout Africa relative to other major global populations (**Supplementary Fig. 7**). The average (s.d., maximum) F_{st} value in this region between the YRI and African-American populations was 0.001 (0.001, 0.015), between the YRI and CEU populations was 0.040 (0.045, 0.304) and between the African-American and CEU populations was 0.011 (0.013, 0.082).

34. Li, Y., Willer, C.J., Ding, J., Scheet, P. & Abecasis, G.R. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet. Epidemiol.* **34**, 816–834 (2010).
35. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* **5**, e1000529 (2009).
36. Browning, S.R. & Browning, B.L. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. *Am. J. Hum. Genet.* **81**, 1084–1097 (2007).
37. Price, A.L. *et al.* Sensitive detection of chromosomal segments of distinct ancestry in admixed populations. *PLoS Genet.* **5**, e1000519 (2009).
38. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
39. Coetzee, S.G., Rhie, S.K., Berman, B.P., Coetzee, G.A. & Noushmehr, H. FunciSNP: an R/bioconductor tool integrating functional non-coding data sets with genetic association studies to identify candidate regulatory SNPs. *Nucleic Acids Res.* **40**, e139 (2012).
40. Bernstein, B.E. *et al.* The NIH Roadmap Epigenomics Mapping Consortium. *Nat. Biotechnol.* **28**, 1045–1048 (2010).
41. Ernst, J. *et al.* Mapping and analysis of chromatin state dynamics in nine human cell types. *Nature* **473**, 43–49 (2011).
42. Bhatia, G. *et al.* Genome-wide comparison of African-ancestry populations from CARe and other cohorts reveals signals of natural selection. *Am. J. Hum. Genet.* **89**, 368–381 (2011).
43. Murray, T. *et al.* African and non-African admixture components in African Americans and an African Caribbean population. *Genet. Epidemiol.* **34**, 561–568 (2010).
44. Voight, B.F., Kudaravalli, S., Wen, X. & Pritchard, J.K. A map of recent positive selection in the human genome. *PLoS Biol.* **4**, e72 (2006).
45. Pickrell, J.K. *et al.* Signals of recent positive selection in a worldwide sample of human populations. *Genome Res.* **19**, 826–837 (2009).
46. Sabeti, P.C. *et al.* Genome-wide detection and characterization of positive selection in human populations. *Nature* **449**, 913–918 (2007).
47. Pritchard, J.K., Stephens, M. & Donnelly, P. Inference of population structure using multilocus genotype data. *Genetics* **155**, 945–959 (2000).
48. Falush, D., Stephens, M. & Pritchard, J.K. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. *Genetics* **164**, 1567–1587 (2003).